N-Benzyllinoleamide
(Synonyms: N-苄基-(9Z,12Z)-十八碳二烯酰胺) 目录号 : GC39090A soluble epoxide hydrolase inhibitor
Cas No.:18286-71-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
N-Benzyl linoleamide is an inhibitor of soluble epoxide hydrolase (sEH; IC50s = 0.155, 0.041, and 0.044 ?M for the human, rat, and mouse enzymes, respectively).1 It is selective for sEH over fatty acid amide hydrolase (FAAH; IC50 = 10.8 ?M for the human enzyme). N-Benzyl linoleamide also inhibits the production of NF-κB (IC50 = 8.80 ?M) and activates nuclear factor erythroid 2-related factor 2 (Nrf2; EC50 = 35.24 ?M in a transactivation assay) in Neuro2a murine neuroblastoma cells.2 It increases the paw withdrawal threshold in a mouse model of LPS-induced inflammatory pain when administered at a dose of 100 mg/kg.1
1.Singh, N., Barnych, B., Morisseau, C., et al.N?Benzyl-linoleamide, a constituent of Lepidium meyenii (maca), is an orally bioavailable soluble epoxide hydrolase inhibitor that alleviates inflammatory painJ. Nat. Prod.83(12)3689-3697(2020) 2.Ticona, L.A., Pérez, V.T., Serban, A.M., et al.Design, synthesis and pharmacological evaluation of N-benzyl linoleamide analogues from Tropaeolum tuberosum as NF-κB inhibitors and Nrf2 activatorsChemistrySelect5(38)11825-11836(2020)
Cas No. | 18286-71-0 | SDF | |
别名 | N-苄基-(9Z,12Z)-十八碳二烯酰胺 | ||
Canonical SMILES | CCCCC/C=C\C/C=C\CCCCCCCC(NCC1=CC=CC=C1)=O | ||
分子式 | C25H39NO | 分子量 | 369.58 |
溶解度 | DMSO : 100 mg/mL (270.58 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7058 mL | 13.5289 mL | 27.0577 mL |
5 mM | 0.5412 mL | 2.7058 mL | 5.4115 mL |
10 mM | 0.2706 mL | 1.3529 mL | 2.7058 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Effects of macamides on endurance capacity and anti-fatigue property in prolonged swimming mice
Pharm Biol 2016;54(5):827-34.PMID:26453017DOI:10.3109/13880209.2015.1087036
Context: Lepidium meyenii Walp. (Brassicaceae), most commonly known as "maca", has been used as a food or folk medicine to improve vitality in Peru. Previous research demonstrated that lipid-soluble extract from maca improved swimming endurance capacity. Macamides are considered the typical lipid-soluble markers for maca and proved to have several pharmacological properties, such as improving sexual performance and neuroprotective activies. Objective: The present study investigates the effects of macamides on endurance capacity and anti-fatigue property in prolonged swimming mice. Materials and methods: The Balb/c mice were divided into seven groups: a control group, low-dose groups of N-Benzyllinoleamide, N-benzyloleamide, and N-benzylpalmitamide, high-dose groups of these macamides. The macamides groups received the commercial products (12 and 40 mg/kg, ig), while the control group received vehicle for 21 d. On the 14th day, the mice were given the weight-loaded swimming test. On the 21st day, the mice were sacrificed immediately after 90 min swimming, and some biochemical parameters were measured. Results and discussion: Compared with the control group, exhaustive swimming time was significantly prolonged in high-dose group of N-benzyloleamide (p < 0.05); the levels of lactic acid (LD), blood ammonia (BA), and lactate dehydrogenase (LDH) were significantly decreased (p < 0.05), whereas the levels of liver glycogen (LG) and non-esterified fatty acid (NEFA) were significantly increased (p < 0.05) in high-dose group of N-benzyloleamide. The malondialdehyde (MDA) contents in the brain, muscle, and liver were significantly decreased (p < 0.05), whereas superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) activities in the brain, muscle, and liver were significantly increased in high-dose group of N-benzyloleamide (p < 0.05). Conclusion: The results indicate that N-benzyloleamide has pharmaceutical property against exercise-induced fatigue, and this effect can be explained by the modulated energy metabolism and improved antioxidant status.